Strategies to Improve Adherence and Clinical Management of Overactive Bladder: Prevalence of OAB and Impact on Quality of Life
Premiere Date: Monday, June 10, 2013This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, June 10, 2014
Note: Credit Is No Longer Available
 | Sender Herschorn, BSc, MDCM, FRCSC Professor Division of Urology University of Toronto Head of the Urodynamics Laboratory Sunnybrook Health Sciences Centre Toronto, ON Canada |
 | Christopher Chapple, BSc, MD, FRCS (Urol) FEBU Consultant Urological Surgeon Royal Hallamshire Hospital Honorary Senior Lecturer of Urology University of Sheffield Visiting Professor of Urology Sheffield Hallam University Chairman of the International Relations Office European Association of Urology Sheffield, UK |
 | Michael B. Chancellor, MD Professor and Director of Neurourology Oakland University William Beaumont School of Medicine Royal Oak, MI |
High discontinuation rates present a substantial barrier to achieving optimal outcomes in all chronic conditions requiring long-term, consistent pharmacotherapy. Discontinuation rates of 80%-90% within the first year of therapy have been reported for overactive bladder (OAB) medications.(1) In order to improve adherence and quality of life for patients with OAB, a proactive and multifaceted approach is needed by clinicians. Frequent and open discussions about side effects or other barriers to pharmacological treatment, or to modify treatment plans and medications can improve adherence. Recommending combined behavioral, psychosocial, and pharmacological therapies along with routine discussions about adherence to treatment can improve the dialogue about the overall management of OAB.
On May 4, 2013, CME Outfitters presented a case-based, interactive symposium featuring a panel that focused on strategies to empower patients in their care with the goal of improving patients’ adherence to the recommended treatments for OAB. To meet the learning preferences of busy clinicians, the symposium has been divided into three short modules, each featuring a video patient case that demonstrates the complex challenges of treatment and medication adherence in patients with OAB at various stages of life—a working mother, a man with complex medical issues, and an elderly woman.
Module 1: Prevalence and Impact on Quality of Life Click here to begin activity now
Module 2: Treatment Click here to access this activity
Module 3: Medication Adherence Click here to access this activity
Each module is certified for .5 AMA PRA Category 1 Credit™. We encourage participants to complete all three modules to optimize the learning experience and to gain valuable insights for treating their patients with OAB.
- D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291-301. PMID: 18439051.
The goal of this activity is to improve clinician knowledge and performance related to discussions with patients about optimal treatment plans and medication adherence in the management of overactive bladder (OAB).
At the end of this CE activity, participants should be able to:
- Recognize the prevalence of OAB and the impact of symptoms on quality of life.
Supported by an educational grant from Astellas Scientific and Medical Affairs, Inc.
Physicians, physician assistants, pharmacists, nurses, and nurse practitioners with an interest in overactive bladder.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs)
Universal Activity Number: 0376-0000-13-010-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST785 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Herschorn has disclosed that he has received grant support from Allergan Inc.; Astellas Pharma Inc.; and Pfizer Inc. He is on the speakers bureau for Allergan Inc.; Astellas Pharma Inc.; Eli Lilly and Company; and Pfizer Inc. He serves as a consultant for Allergan Inc.; Astellas Pharma Inc.; Eli Lilly and Company; and Pfizer Inc.
Professor Chapple has disclosed that he has received research support from Allergan Inc.; Astellas Pharma Inc.; Pfizer Inc.; and Recordati S.p.A. He is on the speakers bureau for Allergan Inc.; Astellas Pharma Inc.; Pfizer Inc.; Ranbaxy Laboratories Limited; and Recordati S.p.A. He serves as a consultant for Allergan Inc.; American Medical Systems, Inc.; Astellas Pharma Inc.; Eli Lilly and Company; Ono Pharmaceutical Co., Ltd; Pfizer Inc.; and Recordati S.p.A.
Dr. Chancellor has disclosed that he receive research support from Allergan Inc.; Cook MyoSite, Inc.; Medtronic, Inc. He serves as a consultant for Allergan Inc.; Astellas Pharma Inc.; Cook MyoSite, Inc.; and Lipella Pharmaceuticals Inc.
Nancy Jennings, MSN, MBA, MHA, RNC (content/peer reviewer) has nothing to disclose.
John M. Rodgers, MD (content/peer reviewer) has nothing to disclose.
Robert Kennedy (planning committee) has nothing to disclose.
Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has nothing to disclose.
Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV1-047-061013-42
